ArticleFrontiers in psychology2026
A study design for modulating two components of the risk architecture of chronic pain: adverse life events and pain catastrophising.
Article in Frontiers in psychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Traumatic experiences and dysfunctional emotional responses to pain modulate pain processing via partly different neural circuits. Modulation of pain experience by brain mechanisms is partly conveyed via descending pathways through the midbrain and brainstem. We designed an intervention study using Eye Movement Desensitization and Reprocessing (EMDR) to desensitize (a) distressing memories of adverse life events (ALE), or (b) pain-related anxiety and emotion dysregulation such as pain catastrophising (PCAT). Our primary objective is to examine the extent to which EMDR efficacy on pain severity and affective symptoms is mediated via these targeted risk factors. The secondary objective is to assess the mediational effects of brain functional and structural markers and functions of the pain modulation circuitry of the brainstem. Methods: This study is a pre-post longitudinal trial with two parallel treatment arms in individuals with chronic primary or secondary pain syndromes. Primary outcomes and mediators of interest include measures of pain severity (intensity, interference, pain-related distress) and affective symptoms (anxiety, depression, tension, irritability) assessed at baseline and post-treatment. Secondary outcomes include structural and functional brain imaging (fMRI), smartphone-based ecological momentary assessment (EMA), biosampling (blood, stool), somatosensory testing (tender point count, quantitative sensory testing, pressure cuff algometry, nociceptive predictive processing) and self-reported measures on pain and affective symptoms. EMDR treatment will consist of six sessions over the course of 2 weeks. Outcome assessors will be blinded to treatment allocation. Mediational analyses will be conducted within a parallel mediation framework using structural equation modeling. Discussion: This study aims to investigate the mechanism of how an EMDR intervention with one of two different foci influences clinical outcomes by mediation analysis. We hypothesize that (1) EMDR treatment focussing on ALE will lead to a decrease in pain severity and affective symptoms through a decrease in arousal symptoms and engagement of paraventricular thalamus and ventral striatum, and (2) that EMDR treatment focussing on pain-related anxiety and emotion dysregulation will lead to a decrease in pain severity and affective symptoms through a decrease in PCAT and strengthening of prefrontal-limbic and brainstem controls. Clinical trial registration: https://www.drks.de, identifier DRKS00039123.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.